Clinical trial
A Multicenter, Randomized, Double-Blind, Exploratory Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
NCT07147114 is registered in ClinicalTrials.gov with Gachon University Gil Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Exploratory Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
- Lead sponsor
- Gachon University Gil Medical Center
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- November 24, 2025
- Completion date
- September 30, 2027
- Enrollment
- 64 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
combined pre- and post-capillary pulmonary hypertension, cpcph, group 2 pulmonary hypertension, hfmref, hfpef